The interim president and CEO, David D. Stevens, will remain chairman of the Board. Mr. Palmisano most recently served as president and CEO of ev3, a global endovascular device company, where he was able to triple the company’s market capitalization during his two-year tenure.
The company’s compensation committee of its board of directors has approved a stock option in addition to regular compensation to Mr. Palmisano.
Related Articles on Orthopedic Device Companies:
DJO Global Launches New Technology to Combat Knee Pain
BioMedGPS Launches SmartTRAK Shoulder Recon Module
42 Orthopedic and Spine Devices Receive FDA 510(k) Clearance in August
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
